Unity Biotechnology (UBX) Stock Statistics & Valuation Metrics

Unity Biotechnology has a market cap or net worth of $16.69M. The enterprise value is $20.16M.

Unity Biotechnology has 16.87M shares outstanding. The number of shares has decreased by -2.65% in one year.

Unity Biotechnology’s return on equity (ROE) is -4.00 and return on invested capital (ROIC) is -109.75%.

The current PE Ratio of Unity Biotechnology is -0.63. Unity Biotechnology’s PEG ratio is 0.01.

In the last 12 months, Unity Biotechnology had revenue of $0.00 and earned -$25.99M in profits. Earnings per share was -$1.54.

In the last 12 months, operating cash flow was -$20.86M and capital expenditures $0.00, giving a free cash flow of -$20.86M billion.

Unity Biotechnology pays an annual dividend of , resulting in a dividend yield of

Unity Biotechnology upcoming earnings date is May 13, 2025, After Close.

Unity Biotechnology as a current ratio of 2.62, with Debt / Equity ratio of 3.03

In the past 12 months, Unity Biotechnology has paid $0.00 in taxes.

Unity Biotechnology EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -1.37.

Unity Biotechnology has $23.23M in cash and marketable securities with $23.54M in debt, giving a net cash position of $309.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Unity Biotechnology is $4.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy